Developer docs
API playgroundTry for free, no card

Search company profiles

Myosin Therapeutics

Full company profile

uuid0000msp

Namestring
Myosin Therapeutics
Legal namestring
Myosin Therapeutics Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Myosin Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2020 as a spinout from The Wertheim UF Scripps Institute (formerly Scripps Research, Florida) by neuroscientist Courtney Miller and medicinal chemists Patrick Griffin and Theodore Kamenecka. The company is developing first-in-class small molecule therapeutics that target molecular nanomotor proteins, with a primary focus on dual non-muscle myosin IIA/IIB (NMIIA/IIB) inhibitors. The lead asset, MT-125, is an orally bioavailable, brain-penetrant dual NMIIA/IIB inhibitor being evaluated in the Phase 1/2 STAR-GBM trial in newly diagnosed, MGMT unmethylated glioblastoma in collaboration with Mayo Clinic. A second core program, MT-110, targets NMII to reduce motivation for stimulants without impairing natural rewards and is advancing toward a Phase 1 trial for methamphetamine use disorder, with potential expansion to cocaine, alcohol, and opioid use disorders. Two preclinical programs (MT-228 in non-orphan oncology, MT-134 in musculoskeletal indications) extend the platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersJupiter, United States
HQ citystring
Jupiter
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, oncology drug development, CNS disorder treatment, clinical-stage biotechnology, molecular nanomotor inhibitors
Industry1 code
PRIMARYHLAKAFAH
Neuro-Oncology
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles2 records
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Myosin Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics that target molecular nanomotor proteins, specifically non-muscle myosin IIA and IIB (NMIIA/IIB) inhibitors. The company is advancing MT-125 (a brain-penetrant, orally available dual NMIIA/IIB inhibitor) through a Phase 1/2 STAR-GBM clinical trial for newly diagnosed glioblastoma at Mayo Clinic, with MT-110 advancing toward a Phase 1 trial for methamphetamine use disorder and additional preclinical candidates MT-228 (non-orphan oncology) and MT-134 (musculoskeletal) in its pipeline.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1/2 STAR-GBM trial initiated May 2026 with first patient dosed
+2 more records
Product overview1 text field

Myosin Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics that target molecular nanomotor proteins. The company's portfolio consists of a platform technology and multiple drug candidates: MT-125 (dual NMIIA/IIB inhibitor for glioblastoma and other treatment-resistant cancers), MT-110 (for methamphetamine and other substance use disorders), MT-228 (for non-orphan oncology), and MT-134 (for undisclosed musculoskeletal indication). MT-125 is the lead clinical program in Phase 1/2 trials for newly diagnosed glioblastoma, while MT-110 is advancing toward Phase 1 trials for methamphetamine use disorder.

Product and service4 records
1MT-125
CategoryOncology Therapeutics
Description

MT-125 is a brain-penetrant, orally-available first-in-class dual inhibitor of non-muscle myosin IIA and IIB (NMIIA/IIB) being developed for oncology. It targets the cellular mechanics of tumor cells to simultaneously prevent tumor invasion and proliferation while activating tumor cell stress responses leading to their elimination. It is administered with standard radiotherapy in the STAR-GBM trial for newly diagnosed, IDH wildtype, MGMT unmethylated glioblastoma, and is also being evaluated for acute myeloid leukemia and pancreatic adenocarcinoma.

2MT-110
CategoryCNS / Substance Use Disorder Therapeutics
Description

MT-110 is a small molecule that targets molecular nanomotor proteins to reduce motivation for methamphetamine and other stimulants and prevent relapses without impacting natural rewards. It is being developed for methamphetamine use disorder, cocaine use disorder, alcohol use disorder, and opioid use disorder. The program has NIDA/NIH grant support and is advancing toward a Phase 1 clinical trial.

3MT-228
CategoryOncology Therapeutics
Description

MT-228 is an NMIIA/IIB small molecule inhibitor with unique characteristics being pursued for non-orphan oncology indications. It is currently in preclinical development.

4MT-134
CategoryMusculoskeletal Therapeutics
Description

MT-134 is a small molecule therapeutic candidate with an undisclosed musculoskeletal indication. It is currently in preclinical development.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

Collaboration for STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in newly diagnosed glioblastoma. Trial conducted across all three Mayo Clinic clinical research units in Minnesota, Florida (Jacksonville), and Arizona (Scottsdale/Phoenix). Mayo Clinic investigators including Dr. Steven Rosenfeld contributed to preclinical research and serve as principal investigators.

Strategic tierSignificantTypeStrategic or Co-development Partner
Description

Contract research organization providing GMP manufacturing services. Partnered with Myosin for GMP manufacturing of MT-110 to support IND submission and Phase 1 clinical trials. MRI Global has extensive experience in GMP manufacturing with focus on safety, quality, and regulatory compliance.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner listed in company investor and partner logos section.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner listed in company investor and partner logos section.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial CNS-focused biotech developing small molecule therapies for treatment-resistant CNS disorders. Comparable in its small molecule CNS drug development focus and clinical-stage execution, though Axsome has reached commercialization while Myosin is pre-revenue.

TypeBroad incumbent
Description

Clinical-stage oncology biotech developing small molecule precision therapeutics against novel synthetic lethal targets. Comparable as a publicly traded small molecule oncology platform with multiple first-in-class programs, though at a more advanced stage and broader pipeline.

TypeBroad incumbent
Description

Commercial CNS company specializing in treatments for substance use disorders, including opioid and stimulant addiction. Comparable in targeting the same addressable patient population as MT-110, though Indivior is established and focused on opioid dependence specifically.

TypeDirect peer
Description

Clinical-stage oncology biotech developing paxalisib (PI3K/mTOR inhibitor) for newly diagnosed and recurrent glioblastoma. Directly comparable to Myosin's MT-125 in targeting the GBM indication with a small molecule mechanism and Orphan/Fast Track regulatory positioning.

TypeDirect peer
Description

Clinical-stage CNS biotech developing small molecule therapies for neurological and psychiatric disorders with high unmet need. Comparable in targeting underserved CNS indications with first-in-class small molecule mechanisms, with similar stage and capital profile to Myosin.

6Diffusion Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biopharma developing trans sodium crocetinate (TSC) for hypoxic solid tumors including GBM. Comparable small molecule mechanism, GBM lead indication, and clinical-stage development profile targeting treatment-resistant solid tumors.

TypeBroad incumbent
Description

Late-stage precision oncology company developing novel small molecule inhibitors targeting difficult-to-drug cancer targets. Comparable in pioneering first-in-class small molecules against previously undruggable protein classes, though at a substantially more advanced clinical and market scale.

TypeDirect peer
Description

Clinical-stage precision oncology biotech developing small molecule allosteric modulators against novel protein targets. Comparable in its focus on first-in-class small molecule discovery against previously undruggable targets, though with a broader solid tumor pipeline than Myosin's neuro-oncology focus.

TypeBroad incumbent
Description

Clinical-stage biotech developing small molecule and biologic therapies for neurodegenerative diseases with CNS penetrance. Comparable in its emphasis on brain-penetrant small molecules for CNS indications, though Denali operates at significantly greater scale and broader CNS scope.

TypeDirect peer
Description

Clinical-stage oncology company developing VAL-083 (dianhydrogalactitol) for newly diagnosed and recurrent glioblastoma, with FDA Orphan Drug and Fast Track designations. Closely comparable lead indication, regulatory strategy, and clinical-stage profile to Myosin Therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Myosin Therapeutics

Biopharmaceuticalsmyosintherapeutics.com

What Myosin Therapeutics does

Myosin Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2020 as a spinout from The Wertheim UF Scripps Institute (formerly Scripps Research, Florida) by neuroscientist Courtney Miller and medicinal chemists Patrick Griffin and Theodore Kamenecka. The company is developing first-in-class small molecule therapeutics that target molecular nanomotor proteins, with a primary focus on dual non-muscle myosin IIA/IIB (NMIIA/IIB) inhibitors. The lead asset, MT-125, is an orally bioavailable, brain-penetrant dual NMIIA/IIB inhibitor being evaluated in the Phase 1/2 STAR-GBM trial in newly diagnosed, MGMT unmethylated glioblastoma in collaboration with Mayo Clinic. A second core program, MT-110, targets NMII to reduce motivation for stimulants without impairing natural rewards and is advancing toward a Phase 1 trial for methamphetamine use disorder, with potential expansion to cocaine, alcohol, and opioid use disorders. Two preclinical programs (MT-228 in non-orphan oncology, MT-134 in musculoskeletal indications) extend the platform.

Myosin Therapeutics firmographics

Firmographics
Name
Myosin Therapeutics
Legal name
Myosin Therapeutics Inc.
Website
https://myosintherapeutics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Myosin Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAFAH
Neuro-Oncology

Keywords

  • Small molecule therapeutics
  • Oncology drug development
  • CNS disorder treatment
  • Clinical-stage biotechnology
  • Molecular nanomotor inhibitors

Where Myosin Therapeutics is headquartered

Location

Headquarters

HQ city
Jupiter
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Myosin Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Distribution channels1 record

Marketing channels8 records

Myosin Therapeutics product offering

Product offering

Core offering

Myosin Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics that target molecular nanomotor proteins, specifically non-muscle myosin IIA and IIB (NMIIA/IIB) inhibitors. The company is advancing MT-125 (a brain-penetrant, orally available dual NMIIA/IIB inhibitor) through a Phase 1/2 STAR-GBM clinical trial for newly diagnosed glioblastoma at Mayo Clinic, with MT-110 advancing toward a Phase 1 trial for methamphetamine use disorder and additional preclinical candidates MT-228 (non-orphan oncology) and MT-134 (musculoskeletal) in its pipeline.

Product overview

Myosin Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics that target molecular nanomotor proteins. The company's portfolio consists of a platform technology and multiple drug candidates: MT-125 (dual NMIIA/IIB inhibitor for glioblastoma and other treatment-resistant cancers), MT-110 (for methamphetamine and other substance use disorders), MT-228 (for non-orphan oncology), and MT-134 (for undisclosed musculoskeletal indication). MT-125 is the lead clinical program in Phase 1/2 trials for newly diagnosed glioblastoma, while MT-110 is advancing toward Phase 1 trials for methamphetamine use disorder.

Differentiator

Problem solved

Functional benefit

Products and services

  • MT-125 MT-125 is a brain-penetrant, orally-available first-in-class dual inhibitor of non-muscle myosin IIA and IIB (NMIIA/IIB) being developed for oncology. It targets the cellular mechanics of tumor cells to simultaneously prevent tumor invasion and proliferation while activating tumor cell stress responses leading to their elimination. It is administered with standard radiotherapy in the STAR-GBM trial for newly diagnosed, IDH wildtype, MGMT unmethylated glioblastoma, and is also being evaluated for acute myeloid leukemia and pancreatic adenocarcinoma.
  • MT-110 MT-110 is a small molecule that targets molecular nanomotor proteins to reduce motivation for methamphetamine and other stimulants and prevent relapses without impacting natural rewards. It is being developed for methamphetamine use disorder, cocaine use disorder, alcohol use disorder, and opioid use disorder. The program has NIDA/NIH grant support and is advancing toward a Phase 1 clinical trial.
  • MT-228 MT-228 is an NMIIA/IIB small molecule inhibitor with unique characteristics being pursued for non-orphan oncology indications. It is currently in preclinical development.
  • MT-134 MT-134 is a small molecule therapeutic candidate with an undisclosed musculoskeletal indication. It is currently in preclinical development.

Quantifiable outcome

  • Phase 1/2 STAR-GBM trial initiated May 2026 with first patient dosed
  • +2 more outcomes

Companies that use Myosin Therapeutics

Customer profile

Segments2 records

Ideal customer profiles3 records

Myosin Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Myosin Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, significant and minor.

  • Mayo CliniccoreStrategic or Co-development Partner · 19 May 2026Collaboration for STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in newly diagnosed glioblastoma. Trial conducted across all three Mayo Clinic clinical research units in Minnesota, Florida (Jacksonville), and Arizona (Scottsdale/Phoenix). Mayo Clinic investigators including Dr. Steven Rosenfeld contributed to preclinical research and serve as principal investigators.
  • MRI GlobalsignificantStrategic or Co-development PartnerContract research organization providing GMP manufacturing services. Partnered with Myosin for GMP manufacturing of MT-110 to support IND submission and Phase 1 clinical trials. MRI Global has extensive experience in GMP manufacturing with focus on safety, quality, and regulatory compliance.
  • NYUminorStrategic or Co-development PartnerAcademic partner listed in company investor and partner logos section.
  • Yale UniversityminorStrategic or Co-development PartnerAcademic partner listed in company investor and partner logos section.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Myosin Therapeutics competitors and assessment

Company assessment

Direct peers

  • Axsome Therapeutics: Commercial CNS-focused biotech developing small molecule therapies for treatment-resistant CNS disorders. Comparable in its small molecule CNS drug development focus and clinical-stage execution, though Axsome has reached commercialization while Myosin is pre-revenue.
  • Kazia Therapeutics: Clinical-stage oncology biotech developing paxalisib (PI3K/mTOR inhibitor) for newly diagnosed and recurrent glioblastoma. Directly comparable to Myosin's MT-125 in targeting the GBM indication with a small molecule mechanism and Orphan/Fast Track regulatory positioning.
  • Praxis Precision Medicines: Clinical-stage CNS biotech developing small molecule therapies for neurological and psychiatric disorders with high unmet need. Comparable in targeting underserved CNS indications with first-in-class small molecule mechanisms, with similar stage and capital profile to Myosin.
  • Diffusion Pharmaceuticals: Clinical-stage biopharma developing trans sodium crocetinate (TSC) for hypoxic solid tumors including GBM. Comparable small molecule mechanism, GBM lead indication, and clinical-stage development profile targeting treatment-resistant solid tumors.
  • Black Diamond Therapeutics: Clinical-stage precision oncology biotech developing small molecule allosteric modulators against novel protein targets. Comparable in its focus on first-in-class small molecule discovery against previously undruggable targets, though with a broader solid tumor pipeline than Myosin's neuro-oncology focus.
  • Kintara Therapeutics: Clinical-stage oncology company developing VAL-083 (dianhydrogalactitol) for newly diagnosed and recurrent glioblastoma, with FDA Orphan Drug and Fast Track designations. Closely comparable lead indication, regulatory strategy, and clinical-stage profile to Myosin Therapeutics.

Broad incumbents

  • Tango Therapeutics: Clinical-stage oncology biotech developing small molecule precision therapeutics against novel synthetic lethal targets. Comparable as a publicly traded small molecule oncology platform with multiple first-in-class programs, though at a more advanced stage and broader pipeline.
  • Indivior: Commercial CNS company specializing in treatments for substance use disorders, including opioid and stimulant addiction. Comparable in targeting the same addressable patient population as MT-110, though Indivior is established and focused on opioid dependence specifically.
  • Revolution Medicines: Late-stage precision oncology company developing novel small molecule inhibitors targeting difficult-to-drug cancer targets. Comparable in pioneering first-in-class small molecules against previously undruggable protein classes, though at a substantially more advanced clinical and market scale.
  • Denali Therapeutics: Clinical-stage biotech developing small molecule and biologic therapies for neurodegenerative diseases with CNS penetrance. Comparable in its emphasis on brain-penetrant small molecules for CNS indications, though Denali operates at significantly greater scale and broader CNS scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Myosin Therapeutics social profiles

Digital presence

Myosin Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Myosin Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Myosin Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Myosin Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myosin Therapeutics

What does Myosin Therapeutics do?

Myosin Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics that target molecular nanomotor proteins, specifically non-muscle myosin IIA and IIB (NMIIA/IIB) inhibitors. The company is advancing MT-125 (a brain-penetrant, orally available dual NMIIA/IIB inhibitor) through a Phase 1/2 STAR-GBM clinical trial for newly diagnosed glioblastoma at Mayo Clinic, with MT-110 advancing toward a Phase 1 trial for methamphetamine use disorder and additional preclinical candidates MT-228 (non-orphan oncology) and MT-134 (musculoskeletal) in its pipeline.

Is Myosin Therapeutics a public or private company?

Myosin Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Myosin Therapeutics founded?

Myosin Therapeutics was founded in 2020. It employs 1 to 10 people.

Where is Myosin Therapeutics based?

Myosin Therapeutics is headquartered in Jupiter, United States, in the North America region.

Who are Myosin Therapeutics's main competitors?

Direct peers on record are Axsome Therapeutics, Kazia Therapeutics, Praxis Precision Medicines, Diffusion Pharmaceuticals, Black Diamond Therapeutics and Kintara Therapeutics. Broad incumbents are Tango Therapeutics, Indivior, Revolution Medicines and Denali Therapeutics.

Does Myosin Therapeutics have an API?

No public API is recorded for Myosin Therapeutics.

What industry is Myosin Therapeutics in?

Myosin Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAKAFAH, Neuro-Oncology. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMyosin Therapeutics to Attend Society for Neuro-Oncology 2026 Annual MeetingMyosin Therapeutics executives will attend the Society for Neuro-Oncology 2026 annual meeting in Philadelphia. The company's STAR-GBM trial of MT-125 is progressing ahead of schedule, with Phase 2 expansion planned for early 2027. The trial evaluates the drug in newly diagnosed MGMT unmethylated glioblastoma.PR NewswireMyosin Therapeutics Invited to Present at BioFuture 2026 in New York CityMyosin Therapeutics was invited to present at BioFuture 2026 in New York City, with CEO Courtney Miller speaking on October 27. The company's STAR-GBM trial for glioblastoma is advancing toward Phase 2 dose expansion, and MT-125 has received FDA Orphan Drug and Fast Track designations for malignant gliomas.PR NewswireMyosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed GlioblastomaMyosin Therapeutics announced that the first patient has been dosed in its Phase 1/2 STAR-GBM trial for MT-125, a first-in-class inhibitor of non-muscle myosin II targeting newly diagnosed glioblastoma, in collaboration with the Mayo Clinic across its Minnesota, Florida, and Arizona campuses with support from the National Cancer Institute. MT-125 has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma, supporting an accelerated regulatory pathway. The company is also developing MT-125 for other treatment-resistant cancers including acute myeloid leukemia and pancreatic cancer.BioSpaceMyosin Therapeutics Awarded Florida Cancer Innovation Fund Grant to Support STAR-GBM Clinical TrialMyosin Therapeutics has been awarded $2 million in funding from the Florida Department of Health through the Casey DeSantis Florida Cancer Innovation Fund to support its STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in patients with newly diagnosed glioblastoma. The trial is being conducted in collaboration with Mayo Clinic, with the Jacksonville campus serving as the primary clinical site in Florida. MT-125 has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma, representing meaningful regulatory milestones for the company's lead oncology candidate.National TodayMyosin Therapeutics Awarded $2M Florida Grant for GBM Clinical TrialMyosin Therapeutics, a biotechnology company based in Jupiter, Florida, has been awarded a $2 million grant from the Florida Department of Health's Casey DeSantis Florida Cancer Innovation Fund to support its STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in newly diagnosed glioblastoma patients. The trial, being conducted in collaboration with Mayo Clinic across all three of its U.S. clinical research units, represents the first clinical evaluation of MT-125, which has received both Orphan Drug Designation and Fast Track Designation for glioblastoma. The funding, awarded in March 2026, is intended to accelerate the clinical development of the oncology therapeutic candidate targeting aggressive cancers.AijournMyosin Therapeutics Awarded Florida Cancer Innovation Fund Grant to Support STAR-GBM Clinical TrialMyosin Therapeutics has been awarded $2 million in funding from the Florida Department of Health through the Casey DeSantis Florida Cancer Innovation Fund to support its STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in patients with newly diagnosed glioblastoma. The trial, being conducted in collaboration with Mayo Clinic with all three U.S. clinical research units participating, represents the first clinical evaluation of MT-125, which has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma. The funding reflects Florida's growing investment in biotechnology innovation and support for emerging biotech companies translating scientific discoveries into clinical programs.PR NewswireMyosin Therapeutics Awarded Florida Cancer Innovation Fund Grant to Support STAR-GBM Clinical TrialMyosin Therapeutics has been awarded $2 million in funding from the Florida Department of Health through the Casey DeSantis Florida Cancer Innovation Fund to support the company's STAR-GBM Phase 1/2 clinical trial evaluating MT-125 in patients newly diagnosed with glioblastoma. The trial is being conducted in collaboration with Mayo Clinic, with all three Mayo Clinic clinical research units in the U.S. participating and clinical activities specifically at the Mayo Clinic campus in Jacksonville, FL. MT-125 has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma, supporting an accelerated regulatory pathway for this first-in-class therapy targeting molecular nanomotor proteins.PR NewswireMyosin Therapeutics Invited to Present at Two South Florida Life Sciences ConferencesMyosin Therapeutics announced it has been invited to present at two South Florida life sciences conferences in March 2026, the Investival Showcase and BioFlorida's South Florida Life Sciences Showcase. The company will present its lead program MT-125, a first-in-class dual non-muscle myosin IIA and IIB inhibitor currently in Phase 1/2 clinical trials for glioblastoma at Mayo Clinic, which has received both Orphan Drug and Fast Track Designations. The conferences provide opportunities for partnering discussions with investors, pharmaceutical companies, and regional life sciences stakeholders.PR NewswireMyosin Therapeutics Invited to Present at Biocom California's Global Partnering & Investor ConferenceMyosin Therapeutics announced it has been selected to present at Biocom California's Global Partnering & Investor Conference, occurring February 24–26, 2026 in La Jolla, California. The company's focus is on oncology, particularly advancing MT-125 in orphan cancers such as glioblastoma, with plans for clinical milestones in 2026.BioSpaceMyosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in GlioblastomaMyosin Therapeutics received a $4.5M NCI SBIR Bridge Award to advance its Phase I trial of MT-125 in glioblastoma. The trial assesses safety, tolerability, and pharmacokinetics of the small molecule targeting non-muscle myosin II. Patient enrollment is set to begin in November.